Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Jazz Pharmaceuticals' Re-Rating Story Has Legs

Jazz Pharmaceuticals PLC $JAZZ Stake Boosted by Bank of America Corp DE

Jazz Pharmaceuticals Q2 Earnings Call Highlights

Amundi Acquires 53,454 Shares of Jazz Pharmaceuticals PLC $JAZZ

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript

Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key Metrics

Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates

Jazz Pharmaceuticals Q2 Earnings Call Highlights

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

Aristotle Global Equity Advisory Q2 2026 Portfolio Review

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term